Patent application number | Description | Published |
20100048489 | Stable Solid Formulation of A GC-C Receptor Agonist Polypeptide Suitable for Oral Administration - Solid, stable formulations of linaclotide suitable for oral administration are described herein as are methods for preparing such formulations. The formulations described herein contain a polypeptide consisting of the amino acid sequence Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (“linaclotide”) or a pharmaceutically acceptable salt thereof. The linaclotide formulations described herein are stable and have a sufficient shelf life for manufacturing, storing and distributing the drug. | 02-25-2010 |
20100074949 | Pharmaceutical composition and administration thereof - The present invention relates to pharmaceutical compositions comprising a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide, methods of manufacturing pharmaceutical compositions of the present invention, and methods of administering pharmaceutical compositions of the present invention. | 03-25-2010 |
20110059903 | Formulations Comprising Linaclotide - The present invention relates to stable compositions comprising linaclotide, as well as to various methods and processes for the preparation and use of the compositions. | 03-10-2011 |
20120009225 | Stable Solid Formulation of Therapeutic Polypeptides Suitable for Oral Administration - Solid, stable formulations of therapeutic polypeptide suitable for oral administration are described herein as are methods for preparing such formulations. The therapeutic polypeptide formulations described herein are stable and have a sufficient shelf life for manufacturing, storing and distributing the drug. | 01-12-2012 |
20120039949 | Stable Solid Formulations of GC-C Receptor Agonist Polypeptides Suitable for Oral Administration - Solid, stable formulations of GC-C receptor agonist polypeptide suitable for oral administration are described herein as are methods for preparing such formulations. The GC-C receptor agonist polypeptide formulations described herein are stable and have a sufficient shelf life for manufacturing, storing and distributing the drug. | 02-16-2012 |
20120213846 | Stable Solid Formulation of a GC-C Receptor Agonist Polypeptide Suitable for Oral Administration - Solid, stable formulations of linaclotide suitable for oral administration are described herein as are methods for preparing such formulations. The formulations described herein contain a polypeptide consisting of the amino acid sequence Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (“linaclotide”) or a pharmaceutically acceptable salt thereof. The linaclotide formulations described herein are stable and have a sufficient shelf life for manufacturing, storing and distributing the drug. | 08-23-2012 |
20120220625 | PHARMACEUTICAL COMPOSITION AND ADMINISTRATIONS THEREOF - The present invention relates to pharmaceutical compositions comprising a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide, methods of manufacturing pharmaceutical compositions of the present invention, and methods of administering pharmaceutical compositions of the present invention. | 08-30-2012 |
20120258983 | Pharmaceutical Composition and Administrations Thereof - The present invention relates to pharmaceutical compositions comprising a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide, methods of manufacturing pharmaceutical compositions of the present invention, and methods of administering pharmaceutical compositions of the present invention. | 10-11-2012 |
20130012454 | Orally Disintegrating Compositions of Linaclotide - The present invention relates to orally disintegrating or dissolving pharmaceutical compositions comprising linaclotide or pharmaceutically acceptable salts thereof, as well to various methods and processes for the preparation and use of the compositions. | 01-10-2013 |
20130059797 | Linaclotide for the Treatment of Chronic Constipation - The invention provides methods for treating a patient with chronic constipation by administering a therapeutically effective dose of linaclotide. | 03-07-2013 |
20130190239 | Formulations Comprising Linaclotide - The present invention relates to stable compositions comprising linaclotide, as well as to various methods and processes for the preparation and use of the compositions. | 07-25-2013 |
20130273169 | Stable Solid Formulation of GC-C Receptor Agonist Polypeptide Suitable for Oral Administration - Solid, stable formulations of linaclotide suitable for oral administration are described herein as are methods for preparing such formulations. The formulations described herein contain a polypeptide consisting of the amino acid sequence Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (“linaclotide”; SEQ ID NO:1) or a pharmaceutically acceptable salt thereof. The linaclotide formulations described herein are stable and have a sufficient shelf life for manufacturing, storing and distributing the drug. | 10-17-2013 |
20140112988 | Pharmaceutical Composition and Administrations Thereof - The present invention relates to pharmaceutical compositions comprising a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide, methods of manufacturing pharmaceutical compositions of the present invention, and methods of administering pharmaceutical compositions of the present invention. | 04-24-2014 |
20140287034 | Stable Solid Formulation of a GC-C Receptor Agonist Polypeptide Suitable for Oral Administration - Solid, stable formulations of linaclotide suitable for oral administration are described herein as are methods for preparing such formulations. The formulations described herein contain a polypeptide consisting of the amino acid sequence Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (“linaclotide”; SEQ ID NO:1) or a pharmaceutically acceptable salt thereof. The linaclotide formulations described herein are stable and have a sufficient shelf life for manufacturing, storing and distributing the drug. | 09-25-2014 |
20140315948 | Pharmaceutical Composition and Administrations Thereof - The present invention relates to pharmaceutical compositions comprising a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide, methods of manufacturing pharmaceutical compositions of the present invention, and methods of administering pharmaceutical compositions of the present invention. | 10-23-2014 |
20140349948 | Treatment of Chronic Constipation - The invention provides methods for treating a patient with chronic constipation by administering a therapeutically effective dose of linaclotide. | 11-27-2014 |
20150031632 | Orally Disintegrating Compositions of Linaclotide - The present invention relates to orally disintegrating or dissolving pharmaceutical compositions comprising linaclotide or pharmaceutically acceptable salts thereof, as well as to various methods and processes for the preparation and use of the compositions. | 01-29-2015 |
20150132375 | Stable Solid Formulation of a GC-C Receptor Agonist Polypeptide Suitable for Oral Administration - Solid, stable formulations of linaclotide suitable for oral administration are described herein as are methods for preparing such formulations. The formulations described herein contain a polypeptide consisting of the amino acid sequence Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (“linaclotide”; SEQ ID NO:1) or a pharmaceutically acceptable salt thereof. The linaclotide formulations described herein are stable and have a sufficient shelf life for manufacturing, storing and distributing the drug. | 05-14-2015 |
Patent application number | Description | Published |
20090158705 | Hypermixing Fluid Ejector - The present invention provides a hypermixing fluid ejector. The ejector includes a reservoir containing a primary fluid and an ejector nozzle with a trailing-edge array of rectilinear orifices. The primary fluid is ejected through these orifices to entrain a secondary fluid, thereby creating a mixed fluid flow. A dividing line is defined on the trailing surface of the nozzle that is orthogonal to the linear axis of the ejector, and the orifices alternate above and below this dividing line in an abutting, offset manner. The orifices are geometrically inclined to produce spray cones that are convergent relative to this dividing line, resulting in convergent helical hypermixing of the primary fluid with the secondary fluid. | 06-25-2009 |
20090158744 | Statically-Operating Ejector Ramjet - The present invention provides a statically starting and operating ramjet engine system. The system includes a pumping ejector coupled to a ramjet engine upstream of the ramjet inlet. A subsonic converging nozzle is placed in fluid communication between the pumping ejector and ramjet inlet. The pumping ejector ejects a primary fluid into the ramjet inlet to entrain a secondary fluid and create a mixed flow with sufficient momentum and internal energy to achieve characteristic speed. The converging nozzle provides a characteristic cross section necessary for the mixed flow to achieve characteristic speed as it moves through the nozzle, thereby producing a standing shock wave at the point of maximum convergence of the nozzle and creating sonic conditions at the inlet of the ramjet engine. | 06-25-2009 |
20090158745 | Ramjet Superheater - The present invention provides a regenerative superheater system for an ejector ramjet engine. The invention includes a superheater in thermal communication with the combustion chamber of the ramjet engine. The superheater transfers thermal energy from combustion chamber to an ejectant which is then redirected upstream to the ramjet ejector. In one embodiment of the invention the temperature of the ejectant is modulated by a variable geometry cooler that controls the amount of thermal energy removed from the superheater system by ambient air. In an alternate embodiment of the invention, the temperature of the ejectant is modulated by a variable geometry superheater that controls the amount of thermal energy added to the superheater system through combustion gas. | 06-25-2009 |
20090162213 | Pumping Ejector - The present invention provides a fluid pumping ejector. The ejector includes a reservoir containing a primary fluid and a mixing duct. An ejector nozzle ejects the primary fluid from said reservoir into the mixing duct to entrain a secondary fluid and create a mixed flow with sufficient momentum and internal energy to achieve characteristic speed. A subsonic converging nozzle is coupled to the mixing duct downstream of the ejector nozzle and provides a characteristic cross section necessary for the mixed flow to achieve characteristic speed as it moves through said converging nozzle, thereby producing a standing shock wave at the point of maximum convergence of the nozzle. The ejector nozzle is fully-expanded, wherein exit speed of the primary fluid is supersonic and exit static pressure of the primary fluid is equal to secondary fluid pressure. | 06-25-2009 |
20130199154 | RAMJET SUPERHEATER - The present invention provides a regenerative superheater system for an ejector ramjet engine. The invention includes a superheater in thermal communication with the combustion chamber of the ramjet engine. The superheater transfers thermal energy from combustion chamber to an ejectant which is then redirected upstream to the ramjet ejector. In one embodiment of the invention the temperature of the ejectant is modulated by a variable geometry cooler that controls the amount of thermal energy removed from the superheater system by ambient air. In an alternate embodiment of the invention, the temperature of the ejectant is modulated by a variable geometry superheater that controls the amount of thermal energy added to the superheater system through combustion gas. | 08-08-2013 |